Pharma Growth
- All
- News
- Videos
-
Tax Benefits, Intellectual Property Rights On Pharma Industry's Budget Wishlist
- Tuesday July 9, 2024
- Business News | Press Trust of India
There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies.
-
www.ndtv.com
-
Cough Syrup Deaths In Gambia Hits A Key Growth Area For India
- Friday October 21, 2022
- India News | Reuters
Indian health authorities said on Wednesday they had halted all production of New Delhi-based Maiden Pharmaceuticals after a WHO report that its cough and cold syrups exported to Gambia may be linked to the deaths of dozens of children there.
-
www.ndtv.com
-
Indian Pharma Tycoons Foray Into New Drugs To Shore Up Growth
- Wednesday June 15, 2016
- India News | Ari Altstedter, Bloomberg
Indian drugmakers are embarking on a research spending spree to master more complex therapies and their billionaire founders look willing to absorb the costs.
-
www.ndtv.com
-
Tax Benefits, Intellectual Property Rights On Pharma Industry's Budget Wishlist
- Tuesday July 9, 2024
- Business News | Press Trust of India
There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies.
-
www.ndtv.com
-
Cough Syrup Deaths In Gambia Hits A Key Growth Area For India
- Friday October 21, 2022
- India News | Reuters
Indian health authorities said on Wednesday they had halted all production of New Delhi-based Maiden Pharmaceuticals after a WHO report that its cough and cold syrups exported to Gambia may be linked to the deaths of dozens of children there.
-
www.ndtv.com
-
Indian Pharma Tycoons Foray Into New Drugs To Shore Up Growth
- Wednesday June 15, 2016
- India News | Ari Altstedter, Bloomberg
Indian drugmakers are embarking on a research spending spree to master more complex therapies and their billionaire founders look willing to absorb the costs.
-
www.ndtv.com